What is Title21 Health Solutions?
Title21 Health Solutions operates at the critical intersection of biotechnology and enterprise software. The company provides a comprehensive suite of digital tools designed to replace legacy paper-based workflows in cell and gene therapy, as well as blood and marrow transplant operations. By offering robust platforms for quality management, manufacturing execution, and operational orchestration, Title21 enables life sciences organizations to maintain stringent regulatory compliance while optimizing complex production cycles. Their market position is defined by the transition from manual documentation to automated, data-driven orchestration, a shift that is increasingly vital for modern clinical and manufacturing environments.
How much funding has Title21 Health Solutions raised?
Title21 Health Solutions has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Title21 Health Solutions
PPP
Public-Private Partnership
What's next for Title21 Health Solutions?
With the recent influx of capital, Title21 Health Solutions is well-positioned to accelerate its product development roadmap and expand its footprint in the global life sciences market. The focus will likely shift toward enhancing the interoperability of its manufacturing execution systems and deepening its integration capabilities within clinical workflows. As the demand for digitized, compliant, and scalable therapy production grows, Title21 is poised to leverage its current financial backing to capture additional market share, potentially through strategic partnerships or the expansion of its cloud-based compliance modules. The company remains a key player in the digital transformation of high-stakes medical manufacturing.
See full Title21 Health Solutions company page
